+++ Geschäftszahlen +++: Strafe für Geldwäsche-Verstöße drückt Gewinn der Bank of America
Börsen-Boom und ETF-Nachfrage spülen Blackrock Milliardengewinn in die Kasse +++ Pharma-Auftragsfertiger Lonza setzt Mittelfristziele +++ Der Newsblog.
In the third quarter of 2026, Goldman Sachs reported impressive results with earnings of $5.3 billion (4.7 billion euros), marking a 29% increase compared to the previous year. Analysts had anticipated lower earnings, and the bank's stock saw a gain of over 3% in premarket trading on Tuesday. Goldman Sachs' overall earnings surged nearly 25% to approximately $18.7 billion, driven primarily by a 70% increase in investment bank revenues to $6.4 billion.
Revenue from trading assets, currencies, and commodities declined slightly, but profits from investment banking, fund management, and asset management also rose. Johnson & Johnson experienced challenges due to geopolitical crises, with sales in the medical technology sector weakening due to the Middle East conflict and budget cuts in Europe.
However, the company still exceeded expectations with a strong year-to-date performance. The company's pharmaceutical division, particularly the Tremfya product for immune disorders, saw a 68% sales increase, contributing to a 2.4 billion dollar revenue for the quarter.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
